Abstract The 2022 yearly Think Tank Meeting in Siena, Tuscany (Italy), organized by the
Italian Network for Tumor Biotherapy (NIBIT) Foundation, the Parker Institute for Cancer …

Immune checkpoint therapies (ICT) improve overall survival of patients with cancer but may
cause immune-related adverse events (irAEs) such as myocarditis. Cytotoxic T lymphocyte …

Cancer is a leading cause of morbidity and deaths in solid organ transplant recipients. In
immunocompetent patients, cancer prognosis has been dramatically improved with the …

Purpose: Patients with advanced urothelial carcinoma who fail platinum-containing
chemotherapy (treatment fails) have a poor prognosis and limited treatment options. Recent …

Immune checkpoint inhibitors (ICI) are increasingly used in combination. To understand the
effects of different ICI categories, we characterized changes in circulating autoantibodies in …

Colorectal cancer (CRC) is one of the most common malignancies worldwide and the
second leading cause of cancer-related death. In recent years, the relationship between gut …

Background Pituitary adenomas are one type of intracranial tumor, which can be divided into
microadenoma (≤ 1 cm), macroadenoma (> 1 cm), and giant adenoma (≥ 4 cm) according …

Simple Summary Hepatocellular carcinoma (HCC) represents a worldwide health
challenge, ranking globally as the third most common cause of cancer-related mortality …

Effective T cell differentiation during acute virus infections leads to the generation of effector
T cells that mediate viral clearance, as well as memory T cells that confer protection against …

Immune checkpoint molecules play critical roles in regulating the anti-tumor immune
response, and tumor cells often exploit these pathways to inhibit and evade the immune …